MedPath

Suzhou Ribo Life Science Co., Ltd.

Suzhou Ribo Life Science Co., Ltd. logo
πŸ‡¨πŸ‡³China
Ownership
Holding
Established
2007-01-18
Employees
51
Market Cap
-
Website
http://www.ribolia.com

Clinical Trials

8

Active:2
Completed:4

Trial Phases

3 Phases

Phase 1:6
Phase 2:1
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (8 trials with phase data)β€’ Click on a phase to view related trials

Phase 1
6 (75.0%)
Not Applicable
1 (12.5%)
Phase 2
1 (12.5%)

Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants

Not Applicable
Recruiting
Conditions
Healthy Volunteers
Interventions
Drug: RBD1119
Drug: Placebo
First Posted Date
2025-06-29
Last Posted Date
2025-09-30
Lead Sponsor
Suzhou Ribo Life Science Co. Ltd.
Target Recruit Count
32
Registration Number
NCT07042594
Locations
πŸ‡¦πŸ‡Ί

CMAX Clinical Research, Adelaide, Australia

A Study of RBD1016 in CHB Participants

Phase 2
Active, not recruiting
Conditions
Chronic Hepatitis B
Interventions
First Posted Date
2023-07-27
Last Posted Date
2024-12-05
Lead Sponsor
Suzhou Ribo Life Science Co. Ltd.
Target Recruit Count
48
Registration Number
NCT05961098
Locations
πŸ‡¨πŸ‡³

Prince of Wales Hospital, Hong Kong, China

πŸ‡¨πŸ‡³

Queen Mary Hospital, Hong Kong, China

πŸ‡ΈπŸ‡ͺ

Karolinska University Hospital, Stockholm, Sweden

and more 1 locations

A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022

Phase 1
Completed
Conditions
Hyperlipemia
Interventions
Drug: Placebo
First Posted Date
2023-06-22
Last Posted Date
2025-05-01
Lead Sponsor
Suzhou Ribo Life Science Co. Ltd.
Target Recruit Count
80
Registration Number
NCT05912296
Locations
πŸ‡¨πŸ‡³

Peking Union Medical College Hospital, Beijing, Beijing, China

A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects

Phase 1
Active, not recruiting
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
First Posted Date
2022-12-16
Last Posted Date
2024-12-03
Lead Sponsor
Suzhou Ribo Life Science Co. Ltd.
Target Recruit Count
32
Registration Number
NCT05653037
Locations
πŸ‡¦πŸ‡Ί

Q-Pharm Pty Limited, Brisbane, Australia

A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044

Phase 1
Completed
Conditions
Health Volunteer
Interventions
Drug: Placebo
First Posted Date
2022-09-14
Last Posted Date
2024-12-04
Lead Sponsor
Suzhou Ribo Life Science Co. Ltd.
Target Recruit Count
72
Registration Number
NCT05539651
Locations
πŸ‡¦πŸ‡Ί

Q-Pharm Pty Limited, Brisbane, Australia

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.